AU2014352404B2 - Dihydropyrimidine compounds and their application in pharmaceuticals - Google Patents
Dihydropyrimidine compounds and their application in pharmaceuticals Download PDFInfo
- Publication number
- AU2014352404B2 AU2014352404B2 AU2014352404A AU2014352404A AU2014352404B2 AU 2014352404 B2 AU2014352404 B2 AU 2014352404B2 AU 2014352404 A AU2014352404 A AU 2014352404A AU 2014352404 A AU2014352404 A AU 2014352404A AU 2014352404 B2 AU2014352404 B2 AU 2014352404B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- compound
- mmol
- independently
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *CC(N=C(*)NC1*)=C1C(**)=O Chemical compound *CC(N=C(*)NC1*)=C1C(**)=O 0.000 description 9
- XPALEVKXWXIQRM-QELUHHJYSA-N C/C(/Cl)=C(/[C@@H]1N=C(c2ncc[s]2)NC(CN(C2)[C@H](CCC(O)=O)CCC2(F)F)=C1C(OC)=O)\C=C Chemical compound C/C(/Cl)=C(/[C@@H]1N=C(c2ncc[s]2)NC(CN(C2)[C@H](CCC(O)=O)CCC2(F)F)=C1C(OC)=O)\C=C XPALEVKXWXIQRM-QELUHHJYSA-N 0.000 description 1
- CCPVCZYOGHGBBD-OWLJTODASA-N CC(C[C@H](C1)N(CC(NC(c2ncc[s]2)=N[C@H]2c(ccc(F)c3)c3Cl)=C2C(OC)=O)CC1(F)F)C(O)=O Chemical compound CC(C[C@H](C1)N(CC(NC(c2ncc[s]2)=N[C@H]2c(ccc(F)c3)c3Cl)=C2C(OC)=O)CC1(F)F)C(O)=O CCPVCZYOGHGBBD-OWLJTODASA-N 0.000 description 1
- VZETVCNDZVNTNA-HNHGDDPOSA-N CC1(C[I-][C@H](CCCCC(O)=O)C1)F Chemical compound CC1(C[I-][C@H](CCCCC(O)=O)C1)F VZETVCNDZVNTNA-HNHGDDPOSA-N 0.000 description 1
- JIQRTJRFRXOOQE-AWEZNQCLSA-N CCOC(C1=C(C)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O Chemical compound CCOC(C1=C(C)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O JIQRTJRFRXOOQE-AWEZNQCLSA-N 0.000 description 1
- GSBYZFBWWGLUDE-AJTFCVKESA-N CCOC(C1=C(CN(C2)C(CCC(O)=O)C(C)(C)C2F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(C2)C(CCC(O)=O)C(C)(C)C2F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O GSBYZFBWWGLUDE-AJTFCVKESA-N 0.000 description 1
- UNIBPYFUCIOXPF-JQHMPQBSSA-N CCOC(C1=C(CN(C2)[C@@H](CC(C)C(O)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(C2)[C@@H](CC(C)C(O)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O UNIBPYFUCIOXPF-JQHMPQBSSA-N 0.000 description 1
- WWDXQSYEYUUOKN-UNMCSNQZSA-N CCOC(C1=C(CN(C2)[C@@H](CCC(C)=O)C(C)(C)C2(F)F)NC(c2ncc[s]2)=N[C@H]1c1ccccc1Cl)=O Chemical compound CCOC(C1=C(CN(C2)[C@@H](CCC(C)=O)C(C)(C)C2(F)F)NC(c2ncc[s]2)=N[C@H]1c1ccccc1Cl)=O WWDXQSYEYUUOKN-UNMCSNQZSA-N 0.000 description 1
- DBDKBBQRJYNELV-KKSFZXQISA-N CCOC(C1=C(CN(C2)[C@@H](CCC(C)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(C2)[C@@H](CCC(C)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O DBDKBBQRJYNELV-KKSFZXQISA-N 0.000 description 1
- NHFHJCVFAUXWIZ-KKSFZXQISA-N CCOC(C1=C(CN(C2)[C@@H](CCC(C)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(C2)[C@@H](CCC(C)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O NHFHJCVFAUXWIZ-KKSFZXQISA-N 0.000 description 1
- SGICWDVAQGILPX-DSSKRPNASA-N CCOC(C1=C(CN(C2)[C@H](CCC(O)=O)C(C)(C)C2F)NC(c2ncc[s]2)=N[C@H]1/C(/C=C)=C(/C)\Cl)=O Chemical compound CCOC(C1=C(CN(C2)[C@H](CCC(O)=O)C(C)(C)C2F)NC(c2ncc[s]2)=N[C@H]1/C(/C=C)=C(/C)\Cl)=O SGICWDVAQGILPX-DSSKRPNASA-N 0.000 description 1
- UXFXZBOCQKBHLS-VLIAUNLRSA-N CCOC(C1=C(CN(C2)[C@H](CCC(O)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(C2)[C@H](CCC(O)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O UXFXZBOCQKBHLS-VLIAUNLRSA-N 0.000 description 1
- YBARZJQSVMWKFZ-ZHRRBRCNSA-N CCOC(C1=C(CN(C2)[C@H](CCCCC(O)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(C2)[C@H](CCCCC(O)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O YBARZJQSVMWKFZ-ZHRRBRCNSA-N 0.000 description 1
- IFHIMFZONAFTPT-CXBCTULXSA-N CCOC(C1=C(CN(CC(C2)(F)F)[C@@H]2C(C)CC(O)=O)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Br)=O Chemical compound CCOC(C1=C(CN(CC(C2)(F)F)[C@@H]2C(C)CC(O)=O)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Br)=O IFHIMFZONAFTPT-CXBCTULXSA-N 0.000 description 1
- PKOJDTKJNZKPGE-UHFFFAOYSA-N CCOC(C1=C(CN)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O PKOJDTKJNZKPGE-UHFFFAOYSA-N 0.000 description 1
- HVMPCEHHUXAGFT-XNLYHCEPSA-N CC[IH][F]C1(C(C)(C)[C@H](CCC(C)=O)N(CC(NC(c2ncc[s]2)=N[C@H]2c(c(Cl)c3)ccc3Cl)=C2C(OC)=O)C1)F Chemical compound CC[IH][F]C1(C(C)(C)[C@H](CCC(C)=O)N(CC(NC(c2ncc[s]2)=N[C@H]2c(c(Cl)c3)ccc3Cl)=C2C(OC)=O)C1)F HVMPCEHHUXAGFT-XNLYHCEPSA-N 0.000 description 1
- ZQPVXXUOCLWIJM-YFKPBYRVSA-N OC(CC[C@@H](C1)NCC1(F)F)=O Chemical compound OC(CC[C@@H](C1)NCC1(F)F)=O ZQPVXXUOCLWIJM-YFKPBYRVSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310590683 | 2013-11-19 | ||
| CN201310590683.6 | 2013-11-19 | ||
| CN201410108925.8 | 2014-03-23 | ||
| CN201410108925 | 2014-03-23 | ||
| PCT/CN2014/091444 WO2015074546A1 (en) | 2013-11-19 | 2014-11-18 | Dihydropyrimidine compounds and their application in pharmaceuticals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014352404A1 AU2014352404A1 (en) | 2016-02-18 |
| AU2014352404B2 true AU2014352404B2 (en) | 2018-07-19 |
Family
ID=53178948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014352404A Active AU2014352404B2 (en) | 2013-11-19 | 2014-11-18 | Dihydropyrimidine compounds and their application in pharmaceuticals |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9498479B2 (enExample) |
| EP (1) | EP3071564B1 (enExample) |
| JP (1) | JP6524081B2 (enExample) |
| KR (1) | KR20160077050A (enExample) |
| CN (1) | CN104650068B (enExample) |
| AU (1) | AU2014352404B2 (enExample) |
| CA (1) | CA2920415A1 (enExample) |
| MX (1) | MX2016006564A (enExample) |
| RU (1) | RU2678990C1 (enExample) |
| WO (1) | WO2015074546A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201601813UA (en) | 2013-11-27 | 2016-04-28 | Sunshine Lake Pharma Co Ltd | Processes for preparing dihydropyrimidine derivatives and intermediates thereof |
| RU2682672C2 (ru) | 2014-03-28 | 2019-03-20 | Саншайн Лейк Фарма Ко., Лтд. | Соединения дигидропиримидина и их применение в фармацевтических препаратах |
| CN105859709B (zh) | 2015-02-07 | 2018-12-04 | 广东东阳光药业有限公司 | 二氢嘧啶衍生物的复合物及其在药物中的应用 |
| US10051470B2 (en) | 2015-03-23 | 2018-08-14 | Qualcomm Incorporated | Schedule selection and connection setup between devices participating in a NAN data link |
| WO2016161268A1 (en) | 2015-04-01 | 2016-10-06 | Enanta Pharmaceuticals, Inc. | Hepatitis b antviral agents |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2017011552A1 (en) * | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| BR112018009009A8 (pt) | 2015-11-03 | 2019-02-26 | Hoffmann La Roche | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon |
| US10280175B2 (en) | 2016-02-02 | 2019-05-07 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| EP3411359B1 (en) * | 2016-02-04 | 2021-10-13 | Merck Sharp & Dohme Corp. | Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents |
| MY198617A (en) | 2016-03-07 | 2023-09-11 | Enanta Pharm Inc | Hepatitis b antiviral agents |
| BR112018075465A2 (pt) * | 2016-06-10 | 2019-03-19 | Enanta Pharmaceuticals, Inc. | agentes antivirais de hepatite b |
| EP3503894A1 (en) | 2016-08-24 | 2019-07-03 | H. Hoffnabb-La Roche Ag | Combination therapy of an hbv capsid assembly inhibitor and a nucleos(t)ide analogue |
| US11166954B2 (en) | 2016-11-18 | 2021-11-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Dihydropyrimidine compound and preparation method and use thereof |
| MY194471A (en) * | 2016-11-18 | 2022-11-30 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Dihydropyrimidine compound and preparation method and use thereof |
| KR102665544B1 (ko) * | 2017-06-26 | 2024-05-14 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 디하이드로피리미딘 화합물 및 약제에서의 이의 용도 |
| JP2020525490A (ja) | 2017-06-27 | 2020-08-27 | ヤンセン ファーマシューティカ エヌ．ベー． | ヘテロアリールジヒドロピリミジン誘導体及びｂ型肝炎感染を治療する方法 |
| WO2019046271A1 (en) | 2017-08-28 | 2019-03-07 | Enanta Pharmaceuticals, Inc. | ANTIVIRAL AGENTS AGAINST HEPATITIS B |
| CA3079557A1 (en) * | 2017-10-18 | 2019-04-25 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and uses thereof in medicine |
| WO2019113175A1 (en) | 2017-12-06 | 2019-06-13 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| TW201927789A (zh) | 2017-12-06 | 2019-07-16 | 美商因那塔製藥公司 | B型肝炎抗病毒試劑 |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US10729688B2 (en) | 2018-03-29 | 2020-08-04 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| CN108329308B (zh) | 2018-05-16 | 2022-11-01 | 四川科伦博泰生物医药股份有限公司 | 一种二氢嘧啶类化合物的固体形式及其制备方法 |
| US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
| TW202024093A (zh) | 2018-09-21 | 2020-07-01 | 美商安塔製藥公司 | 作為抗病毒劑之官能化雜環 |
| ES3023937T3 (en) | 2018-10-31 | 2025-06-03 | The Westmead Institute For Medical Res | Pharmaceutical compositions for use in treating an hbv or hdv infection |
| BR112021009854A2 (pt) | 2018-11-21 | 2021-08-17 | Enanta Pharmaceuticals, Inc. | heterociclos funcionalizados como agentes antivirais |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| CN113831359A (zh) * | 2020-06-24 | 2021-12-24 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| CN118955353A (zh) * | 2024-10-14 | 2024-11-15 | 南京恒远科技开发有限公司 | 一种(s)-4,4-二氟-1-甘氨酰吡咯烷-2-氰基的合成方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014037480A1 (en) * | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0202654A3 (en) | 1985-05-20 | 1987-12-16 | E.R. Squibb & Sons, Inc. | 5-carboxy-1,4-dihydropyrimidine derivatives |
| GB8906168D0 (en) | 1989-03-17 | 1989-05-04 | Pfizer Ltd | Therapeutic agents |
| SE9702563D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | Compounds |
| SE9702564D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | New compounds |
| DE19817262A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue 2-heterocyclisch substituierte Dihydropyrimidine |
| DE19817265A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe |
| DE19817264A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
| WO2000058302A1 (de) | 1999-03-25 | 2000-10-05 | Bayer Aktiengesellschaft | Dihydropyrimidine und ihre verwendung zur behandlung von hepatitis b |
| DE10012549A1 (de) | 2000-03-15 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10012823A1 (de) * | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10012824A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10013125A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10013126A1 (de) * | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| WO2005007124A2 (en) | 2003-07-23 | 2005-01-27 | Bristol-Myers Squibb Company | Substituted dihydropyrimidine inhibitors of calcium channel function |
| CN101104617B (zh) | 2006-07-10 | 2010-06-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101104604B (zh) | 2006-07-10 | 2011-03-02 | 北京摩力克科技有限公司 | 光学纯二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101225084A (zh) | 2007-01-16 | 2008-07-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CA2691056C (en) | 2007-06-18 | 2014-03-11 | Zhang, Zhongneng | Bromo-phenyl substituted thiazolyl dihydropyrimidines for treating and preventing hepatitis b infections |
| CN101328168B (zh) * | 2007-06-18 | 2011-09-07 | 张中能 | 一种乙氧碳酰基-取代噻唑二氢嘧啶 |
| CN101328170B (zh) | 2007-06-18 | 2011-09-14 | 张中能 | 一种氟苯基-取代噻唑二氢嘧啶 |
| WO2008154819A1 (fr) | 2007-06-18 | 2008-12-24 | Zhang, Zhongneng | Thiazolyl-dihydropyrimidines à substitution carbéthoxy |
| WO2010069147A1 (zh) | 2008-12-17 | 2010-06-24 | 张中能 | 二氢嘧啶类化合物、其组合物及其应用 |
| CN101744823B (zh) | 2008-12-17 | 2013-06-19 | 广东东阳光药业有限公司 | 一种二氢嘧啶类化合物的固体分散体及其药用制剂 |
| CN101575318B (zh) | 2009-06-25 | 2012-02-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 二氢嘧啶类化合物及其用于制备治疗和/或预防病毒性疾病的药物的用途 |
| US9487534B2 (en) | 2011-08-02 | 2016-11-08 | Scripps Research Institute, A Not-For-Profit Public Benefit Corporation Of California | Modulators of virus assembly as antiviral agents |
| KR102056665B1 (ko) | 2012-01-06 | 2019-12-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 4,4,-이치환-1,4-디하이드로피리미딘 및 b형 간염의 치료를 위한 약제로서 이의 용도 |
| US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| MX2014011749A (es) * | 2012-03-31 | 2015-01-22 | Hoffmann La Roche | 4-metil-dihidropirimidinas novedosas para el tratamiento y la prolifaxis de la infeccion por el virus de la hepatitis b. |
| CA2876690C (en) | 2012-08-24 | 2020-06-09 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and their application in pharmaceuticals |
| CN103664897B (zh) * | 2012-09-01 | 2018-04-03 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| CN103664925B (zh) | 2012-09-07 | 2018-01-23 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| CN103664899B (zh) * | 2012-09-11 | 2017-06-16 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| SG11201503475WA (en) | 2012-11-09 | 2015-05-28 | Univ Indiana Res & Tech Corp | Alternative uses for hbv assembly effectors |
| CN105188703A (zh) | 2013-03-20 | 2015-12-23 | 美国印第安纳大学研究和技术公司 | 荧光-hap：用于细胞中的hbv核的诊断性染色剂 |
| SG11201509463YA (en) | 2013-05-17 | 2015-12-30 | Hoffmann La Roche | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| SG11201601813UA (en) * | 2013-11-27 | 2016-04-28 | Sunshine Lake Pharma Co Ltd | Processes for preparing dihydropyrimidine derivatives and intermediates thereof |
-
2014
- 2014-11-18 RU RU2016122908A patent/RU2678990C1/ru active
- 2014-11-18 EP EP14863769.7A patent/EP3071564B1/en active Active
- 2014-11-18 CA CA2920415A patent/CA2920415A1/en not_active Abandoned
- 2014-11-18 WO PCT/CN2014/091444 patent/WO2015074546A1/en not_active Ceased
- 2014-11-18 KR KR1020167008618A patent/KR20160077050A/ko not_active Withdrawn
- 2014-11-18 US US15/022,562 patent/US9498479B2/en active Active
- 2014-11-18 CN CN201410657898.XA patent/CN104650068B/zh active Active
- 2014-11-18 MX MX2016006564A patent/MX2016006564A/es unknown
- 2014-11-18 JP JP2016530248A patent/JP6524081B2/ja active Active
- 2014-11-18 AU AU2014352404A patent/AU2014352404B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014037480A1 (en) * | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
Also Published As
| Publication number | Publication date |
|---|---|
| US20160206616A1 (en) | 2016-07-21 |
| RU2678990C1 (ru) | 2019-02-05 |
| CN104650068B (zh) | 2018-08-10 |
| JP6524081B2 (ja) | 2019-06-05 |
| AU2014352404A1 (en) | 2016-02-18 |
| CN104650068A (zh) | 2015-05-27 |
| EP3071564A1 (en) | 2016-09-28 |
| WO2015074546A1 (en) | 2015-05-28 |
| US9498479B2 (en) | 2016-11-22 |
| HK1224286A1 (en) | 2017-08-18 |
| RU2016122908A (ru) | 2017-12-25 |
| CA2920415A1 (en) | 2015-05-28 |
| KR20160077050A (ko) | 2016-07-01 |
| EP3071564A4 (en) | 2017-04-26 |
| MX2016006564A (es) | 2017-09-12 |
| JP2016537358A (ja) | 2016-12-01 |
| EP3071564B1 (en) | 2020-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014352404B2 (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| EP3122747B1 (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| US9340538B2 (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| KR102667040B1 (ko) | 디하이드로피리미딘 화합물 및 약제에서의 이의 용도 | |
| CN104650070B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| HK1224286B (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| HK1228400B (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| HK1228400A1 (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| HK1206027B (en) | 2,4,5,6-substituted 3,6-dihydropyrimidine derivatives as hepatitis b virus (hbv) polymerase inhibitors for the treatment of e.g. chronic hepatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY Free format text: FORMER OWNER(S): SUNSHINE LAKE PHARMA CO., LTD. |
|
| PC | Assignment registered |
Owner name: SUNSHINE LAKE PHARMA CO., LTD. Free format text: FORMER OWNER(S): NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED |